Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1668
    +0.0012 (+0.10%)
     

  • GBP/USD

    1.2486
    -0.0025 (-0.20%)
     

  • Bitcoin GBP

    50,984.55
    -410.32 (-0.80%)
     

  • CMC Crypto 200

    1,324.34
    -72.19 (-5.17%)
     

  • S&P 500

    5,108.08
    +59.66 (+1.18%)
     

  • DOW

    38,286.13
    +200.33 (+0.53%)
     

  • CRUDE OIL

    84.03
    +0.46 (+0.55%)
     

  • GOLD FUTURES

    2,347.70
    +5.20 (+0.22%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Company News For Oct 2, 2019

Zacks Equity Research

  • Shares of Roan Resources, Inc. ROAN gained 21.1% after the energy company agreed to be acquired by Citizen Energy in an all-cash transaction valued at $1 billion.

  • Shares of Conformis, Inc. CFMS rose 19.4% after the medical technology company announced it had entered development, license and distribution agreements with Stryker.

  • Shares of Minerva Neurosciences, Inc. NERV declined 26.3% after the clinical-stage biopharmaceutical company delayed the results of its drug for Schizophrenia.

  • Shares of Reed's, Inc. REED dropped 25.7% after the company issued weak guidance for preliminary third-quarter sales.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Reeds, Inc. (REED) : Free Stock Analysis Report
 
ConforMIS, Inc. (CFMS) : Free Stock Analysis Report
 
Minerva Neurosciences, Inc (NERV) : Free Stock Analysis Report
 
Roan Resources, Inc. (ROAN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research